Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
Category: #health  By Pankaj Singh  Date: 2019-11-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody

Cinda Biopharmaceutical, a startup that focuses on treating autoimmune and metabolic diseases, has recently announced the completion of its Phase I clinical study of human epidermal growth factor receptor-2 (HER2) and antibodies against programmed death receptor 1 (PD-1) in China.

According to reliable sources, Cinda had partnered with Hanmi Pharmaceutical to commence this study which focuses on evaluating the results of IBI315, a recombinant fully human IgG1 type anti-PD-1 / HER2 bispecific antibody, on patients with advanced solid malignant tumors along with HER2 expression.

The trial was targeted towards finding the effects of the drug when combined with chemotherapy and when used as a single-agent on advanced solid malignant tumors. It would further test the tolerability, safety and antitumor activity of the drug for Phase II studies in subjects.

Commenting on the progress, Dr. Zhou Hui, Vice President of Medical Science and Strategic Oncology, Cinda Biopharma, said that IBI315 would be the first-ever PD-1 / HER2 bispecific antibody which has managed to get into the clinical development stage. IBI315 is a significant part of Cinda's product portfolio for anti-tumor. Hence, developing this drug would create a substantial clinical value.

Hui added that the company hopes that IBI315 could fulfill the needs of those patients who are searching for a new and effective treatment option. It also hopes to solve major clinical needs while benefiting more patients.

Reportedly, Cinda Biopharmaceutical has also made some significant financial developments lately. In October 2019, the company revealed that it has agreed to place 97,000,000 new shares at HK $24.60 per share.

Sources close to the development claim that this new share offering would accelerate the development of other primary products in the company’s product range that wasn’t earlier disclosed in the original IPO prospectus.
 

Source Credit: http://innoventbio.com/#/news/179

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Roche announces new data from Phase 3 FeDeriCa trial for breast cancer
Roche announces new data from Phase 3 FeDeriCa trial for breast cancer
By Pankaj Singh

Roche Holding, a renowned Swiss healthcare company working in pharmaceuticals and diagnostics, reportedly announced novel data from its Phase 3 FeDeriCa trial. The trial showed the investigational FDC (fixed-dose combination) of pertuzumab (Perjeta&r...

Genentech announces updated data from Venclexta® clinical trials
Genentech announces updated data from Venclexta® clinical trials
By Pankaj Singh

Chronic lymphocytic leukemia (CLL) is a common type of adult leukemia. In the United States, it is estimated that more than 20,000 new cases of CLL will be diagnosed in 2019. With an eye to cure CLL, biotechnology company Genentech, Inc. has recently...

CoSara receives Indian regulatory authorization for its five IVDs
CoSara receives Indian regulatory authorization for its five IVDs
By Pankaj Singh

Co-Diagnostics, a renowned US-based molecular diagnostics company, having a patented, unique platform to develop diagnostics tests reportedly announced that CoSara Diagnostics, the company’s JV for production, has received regulatory clearance ...